Summary
- Profile Type
- Technology offer
- POD Reference
- TOGB20241003015
- Term of Validity
- 3 October 2024 - 3 October 2026
- Company's Country
- United Kingdom
- Type of partnership
- Commercial agreement with technical assistance
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- This award-winning AMR-related innovation combines antimicrobial action with enhanced wound healing using a patented system to generate peracetic acid at infection sites, promoting tissue repair and growth. Applications include wound care, fistula-associated incontinence, UTIs, dental/oral infections, osteomyelitis, and biofilm-associated tumours. The company seeks medical organizations or device manufacturers to advance the technology into clinical trials under research cooperation.
- Full Description
-
Antimicrobial resistance (AMR) is a critical global health issue, complicating infection treatment and increasing disease spread and severity. A significant challenge in this field is biofilms—bacterial clusters forming protective layers that shield bacteria from traditional antimicrobials, rendering treatments ineffective or necessitating higher doses that cause tissue damage, patient pain, and prolonged infections.
A UK company has developed market-leading infection prevention and control (IPC) products, including the first precursor-generated peracetic acid wipe. This wipe has been clinically proven to reduce C. difficile infections by 72% and decrease the spread of multidrug-resistant organisms (MDROs) in a double cross-over study. The technology won the 2025 European Wound Management Association (EWMA) Innovation Competition prize.
The company's primary focus is on chronic wound infections caused by biofilm-forming bacteria like Pseudomonas aeruginosa and Staphylococcus aureus, which pose significant challenges in healthcare. Current treatments often fail to eradicate these biofilms, leading to persistent infections, slow healing, and increased resistance.
Their innovative technology combines powerful antimicrobial action with enhanced wound healing capabilities. Utilizing a patented delivery system, it creates a potent germ-killing agent, peracetic acid, directly at the infection site while fostering tissue repair and growth. This non-antibiotic, antimicrobial technology targets biofilm-related infections in wounds and promotes healing. It generates peracetic acid (PAA) and hydrogen peroxide in situ at the infection site, delivering effective germ-killing action without promoting AMR.
The company's solution aims to address several unmet clinical needs in wound care:
1. Broad Spectrum Efficacy and AMR: Current wound care antimicrobials face increasing resistance and are ineffective in wound exudate or against all pathogen types, especially resistant strains and biofilms. Their product generates peracetic acid, a broad-spectrum oxidizing agent effective against bacteria, fungi, viruses, and spores, with no resistance risk.
2. Tissue Compatibility and Cytotoxicity: Existing topical wound antiseptics can cause irritation, allergic reactions, and damage to host tissues, delaying healing and prolonging infection and pain. Their product has minimal cytotoxicity and supports wound healing through exogenous lactate from the hydrolysis of Poly(lactic-co-glycolic acid) (PLGA). It breaks down into non-toxic byproducts: water, carbon, and hydrogen.
3. Sustained and Controlled Release: Current antimicrobial treatments often provide only short-term bursts of activity, necessitating frequent changes and leading to suboptimal dosing and persistent infection. Their proprietary delivery system encapsulates precursors for sustained, controlled release of antimicrobials, maintaining effective concentrations at the wound site for extended periods.
This solution addresses the infection prevention control (IPC) challenge by disrupting biofilms, offering broad-spectrum activity at low cytotoxicity, thereby reducing infection rates, antimicrobial use, and preventing resistance.
The product is currently at Technology Readiness Level (TRL) 3, having demonstrated antimicrobial efficacy against Gram-positive and Gram-negative bacteria in vitro, with minimal cytotoxicity.
The company is looking to enter into either research and development or co-operation agreements in order to fully commercialise this solution. - Advantages and Innovations
-
Advantages and Innovations:
1. Peracetic Acid: The solution uses peracetic acid, a broad-spectrum oxidizing agent effective against bacteria, fungi, viruses, and spores, with no resistance risk.
2. Tissue Compatibility and Minimal Cytotoxicity: The technology supports wound healing through exogenous lactate from Poly(lactic-co-glycolic acid) (PLGA) hydrolysis, minimizing irritation and allergic reactions.
3. Sustained and Controlled Release: Encapsulation of precursors allows for sustained, controlled release of antimicrobials, maintaining effective concentrations at the wound site, reducing the need for frequent dressing changes and improving treatment efficacy.
4. Biofilm Penetration and Disruption: The solution degrades biofilm matrices and eradicates pathogens within biofilms, addressing one of the most challenging aspects of wound care.
The company's approach combines antimicrobial action with enhanced wound healing, providing a comprehensive solution to chronic wound infections. This non-antibiotic technology targets biofilm-related infections while promoting wound healing, marking a significant advancement in infection prevention and control. - Stage of Development
- Available for demonstration
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR granted
- IPR notes
- Details can be provided
Partner Sought
- Expected Role of a Partner
-
The company is seeking partners who can facilitate the commercialization of their product, such as:
1. Pharmaceutical Companies: To aid in large-scale production, regulatory approval, and distribution.
2. Medical Device Manufacturers: To integrate the antimicrobial technology into various medical devices and wound care products.
3. Healthcare Providers and Hospitals: For clinical trials and real-world application to demonstrate efficacy and gather data.
4. Research Institutions: For further R&D to explore new applications and enhance the technology.
5. Investment Firms: To provide financial support for scaling up operations and market penetration.
6. Distribution Partners: To ensure the product reaches a wide range of healthcare facilities and markets efficiently.
A potential technical partner should have expertise in antimicrobial technologies, wound care product development, and regulatory compliance for medical devices. - Type and Size of Partner
- SME <=10
- Big company
- SME 11-49
- R&D Institution
- SME 50 - 249
- University
- Type of partnership
- Commercial agreement with technical assistance
- Research and development cooperation agreement
Dissemination
- Technology keywords
- 10002013 - Clean Production / Green Technologies
- Market keywords
- 05007007 - Other medical/health related (not elsewhere classified)
- 05007001 - Disposable products
- 05003006 - Other therapeutic (including defibrillators)
- 05005016 - Environmental Medicine, Social Medicine, Sports Medicine
- Sector Groups Involved
- Health
- Targeted countries
- Afghanistan
- Aland Islands
- Albania
- Algeria
- American Samoa
- Andorra
- Angola
- Anguilla
- Antarctica
- Antigua and Barbuda
- Argentina
- Armenia
- Aruba
- Australia
- Austria
- Azerbaijan
- Bahamas
- Bahrain
- Bangladesh
- Barbados
- Belarus
- Belgium
- Belize
- Benin
- Bermuda
- Bhutan
- Bolivia
- Bonaire, Saint Eustatius and Saba
- Bosnia and Herzegovina
- Botswana
- Bouvet Island
- Brazil
- British Indian Ocean Territory
- British Virgin Islands
- Brunei
- Bulgaria
- Burkina Faso
- Burundi
- Cabo Verde
- Cambodia
- Cameroon
- Canada
- Cayman Islands
- Central African Republic
- Chad
- Chile
- China
- Christmas Island
- Cocos Islands
- Colombia
- Comoros
- Cook Islands
- Costa Rica
- Croatia
- Cuba
- Curacao
- Cyprus
- Czechia
- Democratic Republic of the Congo
- Denmark
- Djibouti
- Dominica
- Dominican Republic
- Ecuador
- Egypt
- El Salvador
- Equatorial Guinea
- Eritrea
- Estonia
- Eswatini
- Ethiopia
- Falkland Islands
- Faroe Islands
- Fiji
- Finland
- France
- French Guiana
- French Polynesia
- French Southern Territories
- Gabon
- Gambia
- Georgia
- Germany
- Ghana
- Gibraltar
- Greece
- Greenland
- Grenada
- Guadeloupe
- Guam
- Guatemala
- Guernsey
- Guinea
- Guinea-Bissau
- Guyana
- Haiti
- Heard Island and McDonald Islands
- Honduras
- Hong Kong
- Hungary
- Iceland
- India
- Indonesia
- Iran
- Iraq
- Ireland
- Isle of Man
- Israel
- Italy
- Ivory Coast
- Jamaica
- Japan
- Jersey
- Jordan
- Kazakhstan
- Kenya
- Kiribati
- Kosovo
- Kuwait
- Kyrgyzstan
- Laos
- Latvia
- Lebanon
- Lesotho
- Liberia
- Libya
- Liechtenstein
- Lithuania
- Luxembourg
- Macao
- Madagascar
- Malawi
- Malaysia
- Maldives
- Mali
- Malta
- Marshall Islands
- Martinique
- Mauritania
- Mauritius
- Mayotte
- Mexico
- Micronesia
- Moldova
- Monaco
- Mongolia
- Montenegro
- Montserrat
- Morocco
- Mozambique
- Myanmar
- Namibia
- Nauru
- Nepal
- Netherlands
- Netherlands Antilles
- New Caledonia
- Nicaragua
- Niger
- Nigeria
- Niue
- Norfolk Island
- North Korea
- North Macedonia
- Northern Mariana Islands
- Norway
- Oman
- Pakistan
- Palau
- Palestinian Territory
- Panama
- Papua New Guinea
- Paraguay
- Peru
- Philippines
- Pitcairn
- Poland
- Portugal
- Puerto Rico
- Qatar
- Republic of the Congo
- Reunion
- Romania
- Russia
- Rwanda
- Saint Barthelemy
- Saint Helena
- Saint Kitts and Nevis
- Saint Lucia
- Saint Martin
- Saint Pierre and Miquelon
- Saint Vincent and the Grenadines
- Samoa
- San Marino
- Sao Tome and Principe
- Saudi Arabia
- Senegal
- Serbia
- Seychelles
- Sierra Leone
- Singapore
- Sint Maarten
- Slovakia
- Slovenia
- Solomon Islands
- Somalia
- South Africa
- South Georgia and the South Sandwich Islands
- South Korea
- South Sudan
- Spain
- Sri Lanka
- Sudan
- Suriname
- Svalbard and Jan Mayen
- Sweden
- Switzerland
- Syria
- Taiwan
- Tajikistan
- Tanzania
- Thailand
- Timor Leste
- Togo
- Tokelau
- Tonga
- Trinidad and Tobago
- Tunisia
- Turkey
- Turkmenistan
- Turks and Caicos Islands
- Tuvalu
- U.S. Virgin Islands
- Uganda
- Ukraine
- United Arab Emirates
- United Kingdom
- United States
- United States Minor Outlying Islands
- Uruguay
- Uzbekistan
- Vanuatu
- Vatican
- Venezuela
- Vietnam
- Wallis and Futuna
- Western Sahara
- Yemen
- Zambia
- Zimbabwe